What is the target of anlotinib?

Anlotinib is a multi-target anti-angiogenic drug. Its targets mainly include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and c-Kit. These receptors play key roles in tumor cell growth, spread, and angiogenesis. By precisely inhibiting the activity of these targets, anlotinib can block the growth signal transmission of tumor cells, inhibit the proliferation and spread of tumor cells, and thereby achieve the purpose of treating cancer. At the same time, it can also inhibit the formation of tumor blood vessels, block the nutrient supply to tumor cells, and further weaken the growth ability of tumors. The target inhibition effect of anlotinib is highly specific and selective, which can reduce damage to normal cells and reduce the occurrence of side effects. Therefore, it has shown good efficacy and safety in the treatment of various cancers.